A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

• Status: Terminated
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to withdraw.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University School of Medicine
• Collaborator: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Histologic or serologic proof of metastatic germ cell neoplasm(gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy. Patients w/ seminoma and non-seminoma are eligible, as are women w/ ovarian germ cell tumors.

• Evidence of recurrent or metastatic carcinoma

• Must have received initial cisplatin combination therapy & demonstrated progression following the administration of at least one "salvage" regimen for advanced germ cell neoplasms.

• Patients are eligible after first line platinum bsed chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor, late relapse or progressed w/in 4 wks of last platinum dose.

• immunohistochemical documentation of EGFR expression documented.

• adequate organ function: ANC >/=150,plt >100K, total bilinormal(ULN). Pts w/ liver mets up to 3x ULN.Transaminases up to 1.5 x ULN if alk phos ismets may have alk phos up to 5x ULN. Serum crt
• ECOG performance status 0-2.

Exclusion Criteria:

• Must be 3 weeks post major surgery, radiotherapy, or chemotherapy and hae recovered from all toxicity.

• Active unresolved infection and/or are receiving concurrent treatment with parenteral antibiotics are ineligible.

• Patients requiring steroids for symptomatic brain metastasis are not eligible.

• Pregnant or lactating patients are not eligible.

• Class III/IV heart disease